KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Interest Expenses (2020 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Interest Expenses for 6 consecutive years, with $65.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses rose 67.82% year-over-year to $65.4 million, compared with a TTM value of $229.6 million through Dec 2025, up 61.83%, and an annual FY2025 reading of $252.6 million, up 78.08% over the prior year.
  • Interest Expenses was $65.4 million for Q4 2025 at Alnylam Pharmaceuticals, up from $44.4 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $65.4 million in Q4 2025 and bottomed at $29.0 million in Q1 2023.
  • Average Interest Expenses over 5 years is $39.6 million, with a median of $36.0 million recorded in 2021.
  • The sharpest move saw Interest Expenses tumbled 31.65% in 2023, then skyrocketed 84.79% in 2025.
  • Year by year, Interest Expenses stood at $36.8 million in 2021, then decreased by 18.75% to $29.9 million in 2022, then rose by 4.76% to $31.3 million in 2023, then grew by 24.36% to $39.0 million in 2024, then skyrocketed by 67.82% to $65.4 million in 2025.
  • Business Quant data shows Interest Expenses for ALNY at $65.4 million in Q4 2025, $44.4 million in Q3 2025, and $61.5 million in Q2 2025.